Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR 2021
Shots: The AURORA 2 involves assessing Lupkynis vs control arm in 216 patients who have completed P-III AURORA 1 study for 1 year Results: reduction in UPCR from pre-treatment baseline to year 2 (-3.1 vs -2.1 mg/mg); reduction proteinuria b/w 1 & 2year (1.0 vs 0.6 mg/mg); stable renal function. In general, the interim analysis […]